Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL757493 | 1.00 | DPP4 (0.55) | DPP4HTTALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL757492 | 1.00 | DPP4 (0.55) | DPP4HTTALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL755963 | 0.91 | DPP4 (0.52) | DPP4ALDH1A1CYP3A4CYP2C19L3MBTL1 | |
| SCHEMBL755964 | 0.91 | DPP4 (0.52) | DPP4ALDH1A1CYP3A4CYP2C19L3MBTL1 | |
| SCHEMBL755965 | 0.91 | DPP4 (0.52) | DPP4ALDH1A1CYP3A4CYP2C19L3MBTL1 | |
| SCHEMBL16141394 | 0.91 | DPP4 (0.52) | DPP4ALDH1A1CYP3A4CYP2C19L3MBTL1 | |
| SCHEMBL1243419 | 0.87 | DPP4 (0.71) | DPP4HTTALDH1A1KMT2A | |
| SCHEMBL1243422 | 0.87 | DPP4 (0.71) | DPP4HTTALDH1A1KMT2A | |
| SCHEMBL1243424 | 0.87 | DPP4 (0.71) | DPP4HTTALDH1A1KMT2A | |
| SCHEMBL19972397 | 0.87 | FPR1 (0.49) | HTTALDH1A1CYP3A4CYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1921917-B1 | FUSED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2012-03-21 | — | — | EP | disclosed |
| US-8017624-B2 | Fused aminopiperidines as dipeptidyi peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20090258894-A1 | Fused Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258894-A1 | Fused Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | DPP4 1/4885HTT 2638/4885ALDH1A1 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.